Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129


Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.

Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, Ditzel HJ.

Oncogene. 2019 Nov 11. doi: 10.1038/s41388-019-1096-8. [Epub ahead of print]


Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.

Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, Ditzel HJ.

Oncogene. 2018 Oct;37(41):5585-5586. doi: 10.1038/s41388-018-0495-6. Erratum in: Oncogene. 2019 Nov 11;:.


A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.

Wang B, Li D, Rodriguez-Juarez R, Farfus A, Storozynsky Q, Malach M, Carpenter E, Filkowski J, Lykkesfeldt AE, Kovalchuk O.

BMC Cancer. 2018 Aug 13;18(1):817. doi: 10.1186/s12885-018-4711-0.


Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.

Lykkesfeldt AE, Iversen BR, Jensen MB, Ejlertsen B, Giobbie-Hurder A, Reiter BE, Kirkegaard T, Rasmussen BB.

Acta Oncol. 2018 Jan;57(1):67-73. doi: 10.1080/0284186X.2017.1404126. Epub 2017 Dec 4.


Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D3.

Lundqvist J, Kirkegaard T, Laenkholm AV, Duun-Henriksen AK, Bak M, Feldman D, Lykkesfeldt AE.

J Steroid Biochem Mol Biol. 2018 Mar;177:171-178. doi: 10.1016/j.jsbmb.2017.06.003. Epub 2017 Jun 10.


A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.

L H Weischenfeldt K, Kirkegaard T, Rasmussen BB, Giobbie-Hurder A, Jensen MB, Ejlertsen B, Lykkesfeldt AE.

Acta Oncol. 2017 Sep;56(9):1161-1167. doi: 10.1080/0284186X.2017.1324211. Epub 2017 May 10.


The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer.

Thewes V, Simon R, Hlevnjak M, Schlotter M, Schroeter P, Schmidt K, Wu Y, Anzeneder T, Wang W, Windisch P, Kirchgäßner M, Melling N, Kneisel N, Büttner R, Deuschle U, Sinn HP, Schneeweiss A, Heck S, Kaulfuss S, Hess-Stumpp H, Okun JG, Sauter G, Lykkesfeldt AE, Zapatka M, Radlwimmer B, Lichter P, Tönjes M.

Oncogene. 2017 Jul 20;36(29):4124-4134. doi: 10.1038/onc.2017.32. Epub 2017 Mar 20.


Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response.

Nass N, Dittmer A, Hellwig V, Lange T, Beyer JM, Leyh B, Ignatov A, Weiβenborn C, Kirkegaard T, Lykkesfeldt AE, Kalinski T, Dittmer J.

Oncotarget. 2016 Jun 21;7(25):38408-38426. doi: 10.18632/oncotarget.9493.


Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.

Joshi T, Elias D, Stenvang J, Alves CL, Teng F, Lyng MB, Lykkesfeldt AE, Brünner N, Wang J, Gupta R, Workman CT, Ditzel HJ.

Oncotarget. 2016 Aug 30;7(35):57239-57253. doi: 10.18632/oncotarget.11136.


High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.

Alves CL, Elias D, Lyng M, Bak M, Kirkegaard T, Lykkesfeldt AE, Ditzel HJ.

Clin Cancer Res. 2016 Nov 15;22(22):5514-5526. doi: 10.1158/1078-0432.CCR-15-1984. Epub 2016 Jun 1.


HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.

Alam MW, Persson CU, Reinbothe S, Kazi JU, Rönnstrand L, Wigerup C, Ditzel HJ, Lykkesfeldt AE, Påhlman S, Jögi A.

Oncotarget. 2016 Mar 8;7(10):11238-50. doi: 10.18632/oncotarget.7167.


Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.

Thomsen KG, Lyng MB, Elias D, Vever H, Knoop AS, Lykkesfeldt AE, Lænkholm AV, Ditzel HJ.

Breast Cancer Res Treat. 2015 Dec;154(3):483-94. doi: 10.1007/s10549-015-3644-4. Epub 2015 Nov 19.


Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

Larsen SL, Yde CW, Laenkholm AV, Rasmussen BB, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.

BMC Cancer. 2015 Apr 8;15:239. doi: 10.1186/s12885-015-1210-4.


SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Larsen SL, Laenkholm AV, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.

PLoS One. 2015 Feb 23;10(2):e0118346. doi: 10.1371/journal.pone.0118346. eCollection 2015.


Altered radiation responses of breast cancer cells resistant to hormonal therapy.

Luzhna L, Lykkesfeldt AE, Kovalchuk O.

Oncotarget. 2015 Jan 30;6(3):1678-94.


Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.

Hole S, Pedersen AM, Lykkesfeldt AE, Yde CW.

Breast Cancer Res Treat. 2015 Feb;149(3):715-26. doi: 10.1007/s10549-015-3284-8. Epub 2015 Feb 10.


New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Hole S, Pedersen AM, Hansen SK, Lundqvist J, Yde CW, Lykkesfeldt AE.

Int J Oncol. 2015 Apr;46(4):1481-90. doi: 10.3892/ijo.2015.2850. Epub 2015 Jan 26.


A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Lænkholm AV, Bak M, Lykkesfeldt AE, Yde CW.

Oncogene. 2015 Aug 6;34(32):4199-210. doi: 10.1038/onc.2014.351. Epub 2014 Nov 3.


Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α.

Pedersen AM, Thrane S, Lykkesfeldt AE, Yde CW.

Int J Oncol. 2014 Nov;45(5):2167-75. doi: 10.3892/ijo.2014.2619. Epub 2014 Aug 22.


Differential response to α-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells.

Nass N, Brömme HJ, Hartig R, Korkmaz S, Sel S, Hirche F, Ward A, Simm A, Wiemann S, Lykkesfeldt AE, Roessner A, Kalinski T.

PLoS One. 2014 Jul 1;9(7):e101473. doi: 10.1371/journal.pone.0101473. eCollection 2014. Erratum in: PLoS One. 2014;9(7):e104322.


Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.

Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, Ditzel HJ.

Oncogene. 2015 Apr 9;34(15):1919-27. doi: 10.1038/onc.2014.138. Epub 2014 Jun 2. Erratum in: Oncogene. 2018 Oct;37(41):5585-5586.


The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.

Kirkegaard T, Yde CW, Kveiborg M, Lykkesfeldt AE.

Int J Oncol. 2014 Jul;45(1):393-400. doi: 10.3892/ijo.2014.2434. Epub 2014 May 9.


1α,25-dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells.

Lundqvist J, Yde CW, Lykkesfeldt AE.

Steroids. 2014 Jul;85:30-5. doi: 10.1016/j.steroids.2014.04.001. Epub 2014 Apr 18.


T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.

Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sørensen BS, Lykkesfeldt AE.

Cancer Lett. 2014 Mar 1;344(1):90-100. doi: 10.1016/j.canlet.2013.10.014.


Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.

Lin X, Li J, Yin G, Zhao Q, Elias D, Lykkesfeldt AE, Stenvang J, Brünner N, Wang J, Yang H, Bolund L, Ditzel HJ.

Breast Cancer Res. 2013 Dec 19;15(6):R119. doi: 10.1186/bcr3588.


TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

Bjerre C, Vinther L, Belling KC, Würtz SØ, Yadav R, Lademann U, Rigina O, Do KN, Ditzel HJ, Lykkesfeldt AE, Wang J, Nielsen HB, Brünner N, Gupta R, Schrohl AS, Stenvang J.

Tumour Biol. 2013 Dec;34(6):3839-51. doi: 10.1007/s13277-013-0969-7. Epub 2013 Jul 24.


Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.

Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M.

PLoS One. 2013 May 21;8(5):e64268. doi: 10.1371/journal.pone.0064268. Print 2013.


Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW.

Breast Cancer Res Treat. 2013 May;139(1):71-80. doi: 10.1007/s10549-013-2485-2. Epub 2013 Apr 23.


Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase.

Lundqvist J, Hansen SK, Lykkesfeldt AE.

Biochim Biophys Acta. 2013 Jan;1833(1):40-7. doi: 10.1016/j.bbamcr.2012.10.012. Epub 2012 Oct 18.


Carboplatin treatment of antiestrogen-resistant breast cancer cells.

Larsen MS, Yde CW, Christensen IJ, Lykkesfeldt AE.

Int J Oncol. 2012 Nov;41(5):1863-70. doi: 10.3892/ijo.2012.1623. Epub 2012 Sep 6.


Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.

Larsen MS, Bjerre K, Lykkesfeldt AE, Giobbie-Hurder A, Laenkholm AV, Henriksen KL, Ejlertsen B, Rasmussen BB.

Breast. 2012 Oct;21(5):662-8. doi: 10.1016/j.breast.2012.07.005. Epub 2012 Jul 31.


ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry.

Laenkholm AV, Knoop A, Ejlertsen B, Rudbeck T, Jensen MB, Müller S, Lykkesfeldt AE, Rasmussen BB, Nielsen KV.

Mol Oncol. 2012 Aug;6(4):428-36. doi: 10.1016/j.molonc.2012.04.003. Epub 2012 May 8.


NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.

Yde CW, Emdal KB, Guerra B, Lykkesfeldt AE.

Breast Cancer Res Treat. 2012 Aug;135(1):67-78. doi: 10.1007/s10549-012-2053-1. Epub 2012 Apr 18.


Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy.

Larsen MS, Bjerre K, Giobbie-Hurder A, Lænkholm AV, Henriksen KL, Ejlertsen B, Lykkesfeldt AE, Rasmussen BB.

Acta Oncol. 2012 Jul;51(6):781-9. doi: 10.3109/0284186X.2011.653009. Epub 2012 Mar 30.


Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.

Cutrupi S, Reineri S, Panetto A, Grosso E, Caizzi L, Ricci L, Friard O, Agati S, Scatolini M, Chiorino G, Lykkesfeldt AE, De Bortoli M.

Oncogene. 2012 Oct 4;31(40):4353-61. doi: 10.1038/onc.2011.627. Epub 2012 Jan 16. Erratum in: Oncogene. 2012 Oct 4;31(40):4420.


Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.

Ejlertsen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, Lykkesfeldt AE, Müller S, Gelber RD, Price KN, Rasmussen BB, Viale G, Mouridsen H; Danish Breast Cancer Cooperative Group; BIG 1-98 Collaborative Group; International Breast Cancer Study Group.

Ann Oncol. 2012 May;23(5):1138-44. doi: 10.1093/annonc/mdr438. Epub 2011 Oct 10.


Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer.

Bernsdorf M, Balslev E, Lykkesfeldt AE, Kroman N, Harder E, von der Maase H, Jakobsen EH, Grabau D, Ejlertsen B.

Breast Cancer Res Treat. 2011 Jul;128(1):165-70. doi: 10.1007/s10549-011-1535-x. Epub 2011 Apr 23.


Endocrine potency of wastewater: contents of endocrine disrupting chemicals and effects measured by in vivo and in vitro assays.

Kusk KO, Krüger T, Long M, Taxvig C, Lykkesfeldt AE, Frederiksen H, Andersson AM, Andersen HR, Hansen KM, Nellemann C, Bonefeld-Jørgensen EC.

Environ Toxicol Chem. 2011 Feb;30(2):413-26. doi: 10.1002/etc.385.


FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema RH, Hartman J, Lykkesfeldt AE, Lam EW.

Oncogene. 2010 May 20;29(20):2983-95. doi: 10.1038/onc.2010.47. Epub 2010 Mar 8.


Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR.

Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23.


Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity.

Taxvig C, Elleby A, Sonne-Hansen K, Bonefeld-Jørgensen EC, Vinggaard AM, Lykkesfeldt AE, Nellemann C.

Nutr Cancer. 2010;62(1):122-31. doi: 10.1080/01635580903191577.


Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.

Sonne-Hansen K, Norrie IC, Emdal KB, Benjaminsen RV, Frogne T, Christiansen IJ, Kirkegaard T, Lykkesfeldt AE.

Breast Cancer Res Treat. 2010 Jun;121(3):601-13. doi: 10.1007/s10549-009-0506-y. Epub 2009 Aug 21.


The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells.

Yde CW, Clausen MP, Bennetzen MV, Lykkesfeldt AE, Mouritsen OG, Guerra B.

Anticancer Drugs. 2009 Sep;20(8):723-35. doi: 10.1097/CAD.0b013e32832ec041.


In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlertsen B, Mouridsen HT.

BMC Cancer. 2009 Jun 16;9:185. doi: 10.1186/1471-2407-9-185.


Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.


An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.

Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.

Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.


ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M, Martin LA.

Endocr Relat Cancer. 2008 Dec;15(4):985-1002. doi: 10.1677/ERC-07-0240. Epub 2008 Sep 29.


Development of new predictive markers for endocrine therapy and resistance in breast cancer.

Henriksen KL, Sonne-Hansen K, Kirkegaard T, Frogne T, Lykkesfeldt AE.

Acta Oncol. 2008;47(4):795-801. doi: 10.1080/02841860802026993. Review.


Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ 2nd, de Cremoux P, Stenvang J, Lykkesfeldt AE.

Breast Cancer Res Treat. 2009 Mar;114(2):263-75. doi: 10.1007/s10549-008-0011-8. Epub 2008 Apr 14.


Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20.


Supplemental Content

Loading ...
Support Center